9 December 2020 ID93+GLA-SE candidate TB vaccine appears safe and immunogenic in treated TB patients
The results from the ID93+GLA-SE TB vaccine clinical trial have just been published in the Lancet Respiratory Medicine journal. The candidate vaccine displayed an acceptable safety profile and provides encouraging evidence of vaccine-induced immune responses when given to cured TB patients at the end of treatment.
View abstract online. Click here.
Download media statement. Click here.